期刊
PHARMACOLOGY OF MITOCHONDRIA
卷 240, 期 -, 页码 229-250出版社
SPRINGER-VERLAG BERLIN
DOI: 10.1007/164_2016_6
关键词
ATP; Cardiolipin; Kidney; Mitochondria
资金
- NHLBI NIH HHS [R01 HL123160] Funding Source: Medline
- NIDDK NIH HHS [K08 DK106427, U01 DK104273, R01 DK073608, R01 DK102325] Funding Source: Medline
- NIH HHS [DK106427, DK102325, HL-123160, DK73608] Funding Source: Medline
Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据